|This Slide: #95 of 100|
Slide #95. Valeant Pharmaceuticals International, Inc. — Bausch + Lomb
Valeant Pharmaceuticals International, Inc. (VRX)
Bausch + Lomb
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Bausch + Lomb Holdings Incorporated, the global eye health company, today announced that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash.
Valeant Pharmaceuticals International is a pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). Co. has two operating and reportable segments: Developed Markets, which focuses in dermatology, neurology, gastrointestinal disorders, and eye health therapeutic; and Emerging Markets, which focuses primarily on branded generics, OTC products, and medical devices.
Open the VRX Page at The Online Investor »
Free VRX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Hold (2.46 out of 4)
(ranked higher than approx. 92% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite